Clinical Evaluation of Detection of High Risk HPV in Urine
NCT05210348 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2022-01-27
Summary
Cervical cancer is one of the most common tumors in women, which seriously threatens women's life quality and safety. Human papilloma virus (HPV) infection is the most common cause of cervical cancer. Traditional HPV testing is based on the cells sample shed from the cervix. Recent studies have shown that urine HPV detection can be used as a new HPV detection method. This study intends to include patients undergoing TCT /HPV test/colposcopy in the department of gynecological diseases of the hospital, and collect urine samples and cervical swab samples. Sanger sequencing and cervical swab HPV test results were compared to evaluate the accuracy and clinical validity of urine HPV test combined with clinical diagnosis results of cases.
Conditions
- Human Papillomavirus Infection
- Cervical Cancer
- Human Papilloma Virus
- Negative for Intraepithelial Lesion or Malignancy
- Atypical Squamous Cells of Undetermined Significance
- Cervical Squamous Intraepithelial Lesion
- Atypical Squamous Cells, Cannot Rule Out High-grade Squamous Intraepithelial Lesion
- Low-grade Squamous Intraepithelial Lesion
- High-Grade Squamous Intraepithelial Lesions
- Cervical Intraepithelial Neoplasia Grade I
- Cervical Intraepithelial Neoplasia Grade II
- Cervical Intraepithelial Neoplasia, Grade III
- Atypical Glandular Cells
- Atypical Glandular Cells Not Otherwise Specified
- Atypical Glandular Cells, Favor Neoplastic
- Cervical Squamous Cell Carcinoma
- Adenocarcinoma in Situ
- Cervical Adenocarcinoma
Sponsors & Collaborators
-
Hangzhou Mingze Medical Research Co., Ltd.
collaborator UNKNOWN -
Beijing Tsingke Biological Technology Co., Ltd. Hangzhou Branch
collaborator UNKNOWN -
Hangzhou Newhorizon Health Technology Co., Ltd.
collaborator UNKNOWN -
Peking University People's Hospital
lead OTHER
Eligibility
- Min Age
- 20 Years
- Max Age
- 65 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-09-15
- Primary Completion
- 2022-02-01
- Completion
- 2022-05-01
Countries
- China
Study Locations
More Related Trials
-
Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer
NCT05531981 ·Status: UNKNOWN
-
Third-Generation Nanopore HPV Integration Site for Precise Prediction of Cervical Cancer Prognosis
NCT06644677 ·Status: COMPLETED
-
Evaluation of First-void Urine as an Alternative to Cervical Sampling for Human Papillomavirus (HPV) Testing in Cervical Cancer Screening (Single-center Study).
NCT06254846 ·Status: RECRUITING ·Phase: NA
-
Urinary and Vaginal HPV Testing in Cervical Cancer Screening
NCT05065853 ·Status: UNKNOWN
-
Cervical Cancer Screening Strategies
NCT05309122 ·Status: UNKNOWN
-
HPV Integration Testing for Cervical Cancer Screening
NCT02576158 ·Status: UNKNOWN
-
Application of Plasma Circulating HPV DNA Testing to Management of Cervical Intraepithelial Neoplasia
NCT04274465 ·Status: COMPLETED
-
HPV Test of Urine and Self Collected Vaginal Samples for Cervical Cancer Screening Study
NCT03409471 ·Status: UNKNOWN
-
The Standard Management of HPV Infection
NCT03577925 ·Status: UNKNOWN
-
Detecting HPV DNA in Anal and Cervical Cancers
NCT04857528 ·Status: RECRUITING
-
All-cause and Diseases-specific Mortality of High-risk HPV Infection
NCT06631495 ·Status: NOT_YET_RECRUITING
-
Construction and Validation of a Diagnostic Model for Predicting Molecular Residual Disease and Recurrence of Cervical Cancer Based on Circulating Tumor HPV
NCT06456112 ·Status: NOT_YET_RECRUITING
-
Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women
NCT05570331 ·Status: RECRUITING
-
Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa
NCT05413798 ·Status: RECRUITING ·Phase: NA
-
Prevaccination Study of Cervical Human Papillomavirus Types in Yangtze River Delta Area, China
NCT01487681 ·Status: UNKNOWN
-
Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence
NCT00682552 ·Status: TERMINATED ·Phase: NA
-
Accurate Screening and Prevention of Cervical Lesions-- Development of Accurate Screening Methods for Cervical Lesions
NCT05851079 ·Status: UNKNOWN
-
HPV Integration Testing for Human Papillomavirus-Positive Women
NCT02576262 ·Status: UNKNOWN
-
Low-Cost Molecular Cervical Cancer Screening Study
NCT01231945 ·Status: COMPLETED
-
Research About Impact of HPV Integration on the Prognosis of Women With Persistent HR-HPV Infection
NCT05283239 ·Status: RECRUITING
-
Cervical Cancer Susceptible Population Classification
NCT06405945 ·Status: RECRUITING
-
Cervical Cancer Screening with NGS-HPV Technology Based on Menstrual Blood
NCT06082765 ·Status: RECRUITING
-
The Predictive Role of HPV Integration in HSIL and Cervical Cancer
NCT05300243 ·Status: UNKNOWN
-
DNA Methylation Testing for the Screening of Uterine Cervical Lesion
NCT04646954 ·Status: UNKNOWN ·Phase: PHASE3
-
Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers
NCT05606133 ·Status: RECRUITING ·Phase: NA